SCHEMBL207620

SCHEMBL207620

Fc1ccc2c(c1)CC[CH]N2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR5A P47898 4/20 0.40
KMT2A Q03164 1/20 0.34
PARP1 P09874 1/20 0.33
PARP10 Q53GL7 1/20 0.33
SRD5A1 P18405 1/20 0.33
HTR2C P28335 2/20 0.32
HTR2A P28223 1/20 0.32
AHR P35869 1/20 0.31
NOTUM Q6P988 1/20 0.31
CYP1A2 P05177 1/20 0.31
MAPT P10636 1/20 0.31
CYP2C19 P33261 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
PDE3A Q14432 1/20 0.31
NOX1 Q9Y5S8 1/20 0.31
PKM P14618 1/20 0.31
HTR2B P41595 1/20 0.30
CHRNB2 P17787 1/20 0.30
CHRNB4 P30926 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL208242 0.84 HTR5A (0.40) HTR5AKMT2APARP1PARP10SRD5A1
SCHEMBL208741 0.76 AHR (0.43) HTR5APARP1PARP10SRD5A1HTR2C
SCHEMBL17079530 0.74 HTR5A (0.53) HTR5AKMT2APARP1PARP10SRD5A1
SCHEMBL549063 0.71 DRD2 (0.59) HTR5APARP1PARP10HTR2CHTR2A
Hydrochloric Acid SCHEMBL17799458 0.69 DRD2 (0.57) HTR5APARP1PARP10HTR2CHTR2A
SCHEMBL2216455 0.68 MAPT (0.54) HTR5APARP1PARP10MAPTCA1
SCHEMBL4167607 0.67 HTR5A (0.39) HTR5AKMT2AAHRCYP1A2MAPT
Hydrochloric Acid SCHEMBL19926551 0.67 MAPT (0.57) HTR5APARP1PARP10MAPTCA1
SCHEMBL2233596 0.67 PKM (0.58) HTR5AKMT2ASRD5A1CYP1A2MAPT
SCHEMBL17927787 0.67 MAPT (0.49) HTR5APARP1PARP10MAPTCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1925611-B1 OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME DAIICHI SANKYO CO LTD (JP) 2016-04-13 EP disclosed
EP-1577301-B1 Antithrombotic diaminocyclohexane derivatives DAIICHI SANKYO CO LTD (JP) 2012-09-12 EP disclosed
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-20110312990-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-22 US disclosed
US-8058440-B2 Process for producing 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-11-15 US disclosed
EP-2343290-A1 Diamine derivatives as factor X inhibitors Daiichi Sankyo Company, Limited (JP) 2011-07-13 EP disclosed
US-20110077266-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-03-31 US disclosed
US-20110054177-A1 PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-03-03 US disclosed
US-7880005-B2 reacting 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine with an alkali metal nitrite in the presence of a reducing agent in an aqueous solution of an acidic compound; hydrolysis; industrial scale DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-02-01 US disclosed
EP-2266992-A2 Process for producing thiazole derivative Daiichi Sankyo Company, Limited (JP) 2010-12-29 EP disclosed
US-20070129371-A1 Novel ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-06-07 US disclosed
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-11-09 US disclosed
EP-1683800-A1 PROCESS FOR PRODUCING THIAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-07-26 EP disclosed
US-20050245565-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-03 US disclosed
EP-1577301-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-21 EP disclosed
EP-1577302-A1 NOVEL ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-21 EP disclosed
US-20050119486-A1 Diamine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2005-06-02 US disclosed
US-20050020645-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-27 US disclosed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 EP disclosed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054177-A1 PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID PAH, CA4, TET2 HTR5A 1053/4885KMT2A 546/4885PARP1 1557/4885
US-20070129371-A1 Novel ethylenediamine derivatives C1R, C9, C1S HTR5A 2711/4885KMT2A 3061/4885PARP1 1843/4885
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X F2, C1S, C9 HTR5A 2228/4885KMT2A 3495/4885PARP1 1270/4885
US-20050020645-A1 Diamine derivatives C9, C1S, C1R HTR5A 1546/4885KMT2A 3485/4885PARP1 816/4885
US-20050245565-A1 Diamine derivatives C9, C1S, C1R HTR5A 1546/4885KMT2A 3485/4885PARP1 816/4885
US-20050119486-A1 Diamine derivatives C9, C1S, C1R HTR5A 1546/4885KMT2A 3485/4885PARP1 816/4885
US-20110077266-A1 Diamine Derivatives F2, TFPI, F3 HTR5A 2122/4885KMT2A 1453/4885PARP1 372/4885
US-20110312990-A1 Diamine Derivatives C9, C1S, C1R HTR5A 1505/4885KMT2A 3461/4885PARP1 960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.